Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum

ClinicalTrials.gov ID: NCT01355497

Public ClinicalTrials.gov record NCT01355497. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 6:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy

Study identification

NCT ID
NCT01355497
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GTx
Industry
Enrollment
330 participants

Conditions and interventions

Interventions

  • GTx-024 Drug
  • placebo Drug

Drug

Eligibility (public fields only)

Age range
30 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2011
Primary completion
Apr 30, 2013
Completion
May 31, 2014
Last update posted
Nov 8, 2020

2011 – 2014

United States locations

U.S. sites
30
U.S. states
19
U.S. cities
30
Facility City State ZIP Site status
GTx Investigative Site Birmingham Alabama 35211
GTx Investigative Site Scottsdale Arizona 85255
GTx Investigative Site La Jolla California 92093
GTx Investigative Site Long Beach California 90813
GTx Investigative Site Miami Florida 33133
GTx Investigative Site Orange City Florida 32763
GTx Investigative Site Tampa Florida 33612
GTx Investigative Site Decatur Illinois 62526
GTx Investigative Site Peoria Illinois 61615
GTx Investigative Site Skokie Illinois 60076
GTx Investigative Site Goshen Indiana 46526
GTx Investigative Site Indianapolis Indiana 46260
GTx Investigative Site Ashland Kentucky 41101
GTx Investigative Site Concord Massachusetts 01742
GTx Investigative Site Saint Clair Shores Michigan 48081
GTx Investigative Site Tupelo Mississippi 38801
GTx Investigative Site Great Falls Montana 59405
GTx Investigative Site Rochester New York 14642
GTx Investigative Site Burlington North Carolina 27215
GTx Investigator Flat Rock North Carolina 28731
GTx Investigative Site Wilmington North Carolina 28401
GTx Investigative Site Winston-Salem North Carolina 27103
GTx Investigative Site Canfield Ohio 44406
Gabrail Cancer Center Canton Ohio 44718
GTx Investigative Site Sandusky Ohio 44870
GTx Investigative Site Portland Oregon 97213
GTx Investigative Site Lancaster Pennsylvania 17604
GTx Investigative Site Spartanburg South Carolina 29303
GTx Investigative Site Nashville Tennessee 37203
GTx Investigative Site Round Rock Texas 78665

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01355497, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 8, 2020 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01355497 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →